These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28262588)

  • 21. Genetic and antigenic characterization of influenza A(H3N2) in Cameroon during the 2014-2016 influenza seasons.
    Monamele GC; Vernet MA; Njankouo MR; Victoir K; Akoachere JF; Anong D; Njouom R
    PLoS One; 2017; 12(9):e0184411. PubMed ID: 28877235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The coexistence or replacement of two subtypes of influenza.
    Asaduzzaman SM; Ma J; van den Driessche P
    Math Biosci; 2015 Dec; 270(Pt A):1-9. PubMed ID: 26453807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza vaccination in preventing outbreaks in schools: A long-term ecological overview.
    Pan Y; Wang Q; Yang P; Zhang L; Wu S; Zhang Y; Sun Y; Duan W; Ma C; Zhang M; Zhang X; MacIntyre CR
    Vaccine; 2017 Dec; 35(51):7133-7138. PubMed ID: 29128383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season.
    McLean HQ; Caspard H; Griffin MR; Poehling KA; Gaglani M; Belongia EA; Talbot HK; Peters TR; Murthy K; Ambrose CS
    Vaccine; 2017 May; 35(20):2685-2693. PubMed ID: 28408121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results.
    Andrews N; McMenamin J; Durnall H; Ellis J; Lackenby A; Robertson C; von Wissmann B; Cottrell S; Smyth B; Moore C; Gunson R; Zambon M; Fleming D; Pebody R
    Euro Surveill; 2014 Jul; 19(27):5-13. PubMed ID: 25033051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan.
    Sugaya N; Shinjoh M; Kawakami C; Yamaguchi Y; Yoshida M; Baba H; Ishikawa M; Kono M; Sekiguchi S; Kimiya T; Mitamura K; Fujino M; Komiyama O; Yoshida N; Tsunematsu K; Narabayashi A; Nakata Y; Sato A; Taguchi N; Fujita H; Toki M; Myokai M; Ookawara I; Takahashi T
    Euro Surveill; 2016 Oct; 21(42):. PubMed ID: 27784529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.
    Ansaldi F; Zancolli M; Durando P; Montomoli E; Sticchi L; Del Giudice G; Icardi G
    Vaccine; 2010 Jun; 28(25):4123-9. PubMed ID: 20433807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany.
    Remschmidt C; Rieck T; Bödeker B; Wichmann O
    BMC Infect Dis; 2015 Mar; 15():137. PubMed ID: 25887460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance for influenza--United States, 1997-98, 1998-99, and 1999-00 seasons.
    Brammer TL; Murray EL; Fukuda K; Hall HE; Klimov A; Cox NJ
    MMWR Surveill Summ; 2002 Oct; 51(7):1-10. PubMed ID: 12418623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season.
    Castilla J; Navascués A; Fernández-Alonso M; Reina G; Albéniz E; Pozo F; Álvarez N; Martínez-Baz I; Guevara M; García-Cenoz M; Irisarri F; Casado I; Ezpeleta C;
    Euro Surveill; 2016 Jun; 20(22):. PubMed ID: 27277013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influenza vaccine effectiveness against medically-attended influenza illness during the 2012-2013 season in Beijing, China.
    Yang P; Thompson MG; Ma C; Shi W; Wu S; Zhang D; Wang Q
    Vaccine; 2014 Sep; 32(41):5285-9. PubMed ID: 25092635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection.
    Bragstad K; Vinner L; Hansen MS; Nielsen J; Fomsgaard A
    Vaccine; 2013 Apr; 31(18):2281-8. PubMed ID: 23499598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ten years (2004-2014) of influenza surveillance in Northern Italy.
    Pariani E; Amendola A; Piatti A; Anselmi G; Ranghiero A; Bubba L; Rosa AM; Pellegrinelli L; Binda S; Coppola L; Gramegna M; Zanetti A
    Hum Vaccin Immunother; 2015; 11(1):198-205. PubMed ID: 25483536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.
    Skowronski DM; Janjua NZ; De Serres G; Winter AL; Dickinson JA; Gardy JL; Gubbay J; Fonseca K; Charest H; Crowcroft NS; Fradet MD; Bastien N; Li Y; Krajden M; Sabaiduc S; Petric M
    Clin Infect Dis; 2012 Aug; 55(3):332-42. PubMed ID: 22539661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
    Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
    Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.